CTI BioPharma Corp.Find Ratings Reports
CTI BIOPHARMA CORP's gross profit margin for the fourth quarter of its fiscal year 2017 has significantly decreased when compared to the same period a year ago. Sales and net income fell significantly, underperforming compared to the average company in its industry. CTI BIOPHARMA CORP is extremely liquid. Currently, the Quick Ratio is 2.32 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year, indicating improving cash flow.
At the same time, stockholders' equity ("net worth") has greatly increased by 63.77% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q4 FY17||Q4 FY16|
|Net Sales ($mil)||0.46||9.14|
|Net Income ($mil)||-14.27||-6.37|
|Balance Sheet||Q4 FY17||Q4 FY16|
|Cash & Equiv. ($mil)||43.22||44.0|
|Total Assets ($mil)||54.89||63.84|
|Total Debt ($mil)||14.02||19.26|
|Profitability||Q4 FY17||Q4 FY16|
|Gross Profit Margin||-2585.06||-123.28|
|Return on Assets||-74.09||-81.46|
|Return on Equity||-206.39||-390.48|
|Debt||Q4 FY17||Q4 FY16|
|Share Data||Q4 FY17||Q4 FY16|
|Shares outstanding (mil)||42.97||28.23|
|Div / share||0.0||0.0|
|Book value / share||0.51||0.47|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||402958.0||277743.0|
SELL. This stock’s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. To use another comparison, its price-to-book ratio of 8.00 indicates a significant premium versus the S&P 500 average of 3.22 and a significant discount versus the industry average of 14.28. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CTI BIOPHARMA CORP proves to trade at a discount to investment alternatives within the industry.
|CTIC NM||Peers 38.97||CTIC NM||Peers 29.91|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
CTIC's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
CTIC's P/CF is negative making the measure meaningless.
|CTIC NM||Peers 16.09||CTIC NA||Peers 0.34|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
CTIC's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|CTIC 8.00||Peers 14.28||CTIC 32.11||Peers 1.44|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
CTIC is trading at a significant discount to its peers.
Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
CTIC is expected to have an earnings growth rate that significantly exceeds its peers.
|CTIC 6.94||Peers 61.63||CTIC -56.20||Peers 327.41|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
CTIC is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
CTIC significantly trails its peers on the basis of sales growth